---
document_datetime: 2025-01-20 09:45:02
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/scientific-conclusion/ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_en.pdf
document_name: ocaliva-epar-conclusions-granting-conditional-marketing-authorisation_en.pdf
version: success
processing_time: 0.4883576
conversion_datetime: 2025-12-15 21:53:05.911037
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

<!-- image -->

Conclusions on the granting of the conditional marketing authorisation and presented by the European Medicines Agency Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Conclusions presented by the European Medicines Agency on:

## Â· Conditional marketing authorisation

<!-- image -->